Literature DB >> 30215160

Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages.

Ozgur Mete1, Omalkhaire M Alshaikh2, Amber Cintosun3, Shereen Ezzat2, Sylvia L Asa4.   

Abstract

We report clinicopathological features of a large series of synchronous multiple pituitary neuroendocrine tumors (PitNETs) of different cell lineages. Retrospective review of pathology records from 2001 to 2016 identified 13 synchronous multiple PitNETs from 1055 PitNETs classified using pituitary cell-lineage transcription factors, adenohypohyseal hormones, and other biomarkers. Clinical, radiological, and histopathological features of these tumors were reviewed. The series included seven females and six males. Mean age at diagnosis was 55.23 years (range 36-73). Imaging was unavailable for four patients; among the other nine, mean tumor size was 2.23 cm (range 0.9-3.9). Five patients had acromegaly, four had Cushing disease, and four had clinically non-functional tumors. Twelve had double PitNETs; one had a triple PitNET. The most common tumor type was corticotroph (n = 8; six densely and one sparsely granulated and one Crooke cell; three densely and one sparsely granulated were clinically silent), gonadotroph tumors (n = 8), and somatotroph tumors (n = 5; four sparsely granulated and one densely granulated somatotroph) were followed by lactotroph tumors (n = 4; all sparsely granulated), poorly differentiated Pit-1 lineage tumor (n = 1), and unusual plurihormonal tumor (n = 1). A 54-year-old man with Cushing disease had MEN1-driven Crooke cell and gonadotroph tumors. The triple pitNET consisted of a multilineage plurihormonal tumor associated with a gonadotroph and a sparsely granulated lactotroph tumor. The Ki67 (available from 10 specimens) ranged from 1 to 5% in individual tumors. Radiological and biochemical follow-up was available for 10 and 11 patients, respectively. Radiological tumor persistence/recurrence was identified in three patients with double PitNETs consisting of sparsely granulated lactotroph and gonadotroph tumors (n = 1), sparsely granulated somatotroph and silent corticotroph tumors (n = 1), and gonadotroph and silent corticotroph tumors (n = 1) with cavernous sinus invasion. Biochemical persistence was noted in four patients with double PitNETs consisting of sparsely granulated somatotroph and silent corticotroph tumors (n = 2), gonadotroph and Crooke cell tumors (n = 1), and densely granulated somatotroph and silent corticotroph tumors (n = 1). Multiple PitNETs represent about 1% of PitNETs and usually have hormone excess due to at least one tumor component. Clinical manifestations may be due to the minor component, especially in patients with Cushing disease. Invasive growth and aggressive histological subtypes predicted disease persistence/recurrence. This series also highlights the importance of routine application of pituitary cell lineage transcription factors along with hormones to distinguish and subtype multiple synchronous PitNETs.

Entities:  

Keywords:  Multiple tumors; Pituitary; Synchronous

Mesh:

Year:  2018        PMID: 30215160     DOI: 10.1007/s12022-018-9545-4

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  30 in total

1.  Double adenomas of the pituitary: transcription factors Pit-1, T-pit, and SF-1 identify cytogenesis and differentiation.

Authors:  R A Jastania; K O Alsaad; M Al-Shraim; K Kovacs; S L Asa
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

2.  From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal.

Authors:  S L Asa; O Casar-Borota; P Chanson; E Delgrange; P Earls; S Ezzat; A Grossman; H Ikeda; N Inoshita; N Karavitaki; M Korbonits; E R Laws; M B Lopes; N Maartens; I E McCutcheon; O Mete; H Nishioka; G Raverot; F Roncaroli; W Saeger; L V Syro; A Vasiljevic; C Villa; A Wierinckx; J Trouillas
Journal:  Endocr Relat Cancer       Date:  2017-04       Impact factor: 5.678

3.  Triple pituitary adenoma in Cushing's disease: case report.

Authors:  E Pantelia; G Kontogeorgos; G Piaditis; D Rologis
Journal:  Acta Neurochir (Wien)       Date:  1998       Impact factor: 2.216

4.  Silent somatotroph adenomas of the human pituitary. A morphologic study of three cases including immunocytochemistry, electron microscopy, in vitro examination, and in situ hybridization.

Authors:  K Kovacs; R Lloyd; E Horvath; S L Asa; L Stefaneanu; D W Killinger; H S Smyth
Journal:  Am J Pathol       Date:  1989-02       Impact factor: 4.307

5.  Asynchronous pituitary adenomas with differing morphology.

Authors:  E Thodou; G Kontogeorgos; E Horvath; K Kovacs; H S Smyth; S Ezzat
Journal:  Arch Pathol Lab Med       Date:  1995-08       Impact factor: 5.534

6.  Prevalence of double pituitary adenomas in a surgical series: Clinical, histological and genetic features.

Authors:  F Magri; C Villa; D Locatelli; P Scagnelli; M S Lagonigro; P Morbini; M Castellano; E Gabellieri; M Rotondi; E Solcia; A F Daly; L Chiovato
Journal:  J Endocrinol Invest       Date:  2009-12-01       Impact factor: 4.256

Review 7.  The prevalence of pituitary adenomas: a systematic review.

Authors:  Shereen Ezzat; Sylvia L Asa; William T Couldwell; Charles E Barr; William E Dodge; Mary Lee Vance; Ian E McCutcheon
Journal:  Cancer       Date:  2004-08-01       Impact factor: 6.860

8.  Apparently silent somatotroph adenomas.

Authors:  P Pagesy; J Y Li; M Kujas; F Peillon; O Delalande; A Visot; P Derome
Journal:  Pathol Res Pract       Date:  1991-12       Impact factor: 3.250

9.  Double separate versus contiguous pituitary adenomas: MRI features and endocrinological follow up.

Authors:  Sammie Roberts; Manuel Thomas Borges; Kevin O Lillehei; B K Kleinschmidt-DeMasters
Journal:  Pituitary       Date:  2016-10       Impact factor: 4.107

Review 10.  Overview of the 2017 WHO Classification of Pituitary Tumors.

Authors:  Ozgur Mete; M Beatriz Lopes
Journal:  Endocr Pathol       Date:  2017-09       Impact factor: 3.943

View more
  8 in total

1.  Challenges in the Diagnosis of Pituitary Neuroendocrine Tumors.

Authors:  Sylvia L Asa
Journal:  Endocr Pathol       Date:  2021-04-17       Impact factor: 3.943

Review 2.  Overview of the 2022 WHO Classification of Pituitary Tumors.

Authors:  Sylvia L Asa; Ozgur Mete; Arie Perry; Robert Y Osamura
Journal:  Endocr Pathol       Date:  2022-03-15       Impact factor: 3.943

3.  Multiple tumorous lesions of the pituitary gland.

Authors:  Jannik von Schöning; Jörg Flitsch; Dieter K Lüdecke; Rudolf Fahlbusch; Michael Buchfelder; Rolf Buslei; Ulrich J Knappe; Markus Bergmann; Walter J Schulz-Schaeffer; Jochen Herms; Markus Glatzel; Wolfgang Saeger
Journal:  Hormones (Athens)       Date:  2022-08-10       Impact factor: 3.419

Review 4.  Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification.

Authors:  Ashley B Grossman; Shereen Ezzat; Sylvia L Asa; Ozgur Mete; Michael D Cusimano; Ian E McCutcheon; Arie Perry; Shozo Yamada; Hiroshi Nishioka; Olivera Casar-Borota; Silvia Uccella; Stefano La Rosa
Journal:  Mod Pathol       Date:  2021-05-21       Impact factor: 7.842

5.  Pituitary corticotroph tumour with adrenocortical cells: A distinct clinicopathologic entity with unique morphology and methylation profile.

Authors:  Richard A Hickman; John T Gionco; Phyllis L Faust; Michael L Miller; Jeffrey Bruce; Gabrielle Page-Wilson; Marc K Rosenblum; Sylvia L Asa
Journal:  Neuropathol Appl Neurobiol       Date:  2021-08-09       Impact factor: 6.250

6.  Double pituitary adenomas in a large surgical series.

Authors:  Grzegorz Zieliński; Emir Ahmed Sajjad; Maria Maksymowicz; Monika Pękul; Andrzej Koziarski
Journal:  Pituitary       Date:  2019-12       Impact factor: 4.107

7.  Metachronous double primary neuroendocrine tumors in larynx and lung: a case report.

Authors:  In Hye Song; Youn Soo Lee; Dong-Il Sun; Yong-Kil Hong; Kyo-Young Lee
Journal:  J Int Med Res       Date:  2020-11       Impact factor: 1.671

8.  TWO SYNCHRONOUS PITUITARY ADENOMAS CAUSING CUSHING DISEASE AND ACROMEGALY.

Authors:  Melanie Schorr; Xun Zhang; Wenxiu Zhao; Parisa Abedi; Kate E Lines; E Tessa Hedley-Whyte; Brooke Swearingen; Anne Klibanski; Karen K Miller; Rajesh V Thakker; Lisa B Nachtigall
Journal:  AACE Clin Case Rep       Date:  2019-06-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.